contact us krjpencn

회사 소개

Executive Team

현재 위치: > Executive Team

  • Chunlin Chen, Ph.D. CEO

    Chunlin Chen, Ph.D. Founder/CEO

    Dr. Chen was founder and CEO of Medicilon Inc. Medicilon’s core business is to provide preclinical chemistry, ADMET and biology services to pharmaceutical companies and biotech companies. Prior to founding Medicilon, Dr. Chen had work experience in the USA, as a Staff Investigator at Department of Pharmacokinetics and Metabolism in Vertex Pharmaceuticals and as the Director of Pharmaceutical Department at Parker Hughes Cancer Center.
    In addition, Dr. Chen currently serves as Associate Director for Pharmacokinetics and Drug Metabolism Section of Shanghai Pharmacology Society and visiting Professor for China Pharmaceutical University. Dr. Chen got several awards including Excellent Teacher Award from China Pharmaceutical University, Research Excellent Award from Oklahoma State University and an Excellent returnee award from Chinese government.

  • Guolin Wang, MBA, Chief Advisor

    Guolin Wang, MBA, Chief Advisor

    Mr. Wang holds a masters degree in business administration from the Open University of Hong Kong. Before joining Shanghai Medicilon Inc. in 2008, Mr. Wang has 9 years of middle and senior level management experience in China Telecom, a large-scale state-owned enterprise, and 6 years of senior management experience in China Unicom, a listed company at home and abroad, as well as 3 years of senior management experience in investment management and health care industry. He served as Deputy General Manager in the municipal branch of China Telecom and China Unicom. He also served as General Manager in a health care investment company. He has rich experience on management and investment.

  • Shuangqing Peng Ph.D.  CSO

    Shuangqing Peng Ph.D. CSO

    Ph.D. of pharmacology at Academy of Military Medical Sciences. Post doctor of preventive medicine at Peking University. Post doctor of pharmacology at Michigan State University. Ph.D. supervisor and research fellow at Academy of Military Medical Sciences, vice chairman of China toxicology society, and executive director of China environmental mutagens society. Worked as the director of the national center for drug safety evaluation and research and the director of the toxicology evaluation and research center of the PLA institute of disease control and prevention.
    Undertook the construction of national GLP technology platform, presided over and undertook more than 40 national scientific research projects, including the 973 project, the 863 project and the national science and technology special project of major new drug creation. Has published over 300 scientific papers, including more than 100 SCI papers. Edited and participated in 13 monographs. Won 12 national, provincial and ministerial science and technology achievement awards. Was awarded special government allowance by the state council, post allowance for outstanding military personnel, honorary title of “national outstanding scientific and technological worker” by China association for science and technology, and outstanding contribution award by China toxicology society. Trained more than 90 master, doctoral and postdoctoral students. Academic posts include new drug evaluation expert of the state food and drug administration, medical device evaluation expert, new chemical substance evaluation expert of the ministry of environmental protection and deputy editor of ETAP.

  • Jinna Cai, Ph.D. CBO

    Jinna Cai, Ph.D. CBO

    Dr. Cai completed her whole high-level education at China Pharmaceutical University from Bachelor to Ph.D. Conducted research with Medical University of Toyama and Institution of Natural Medicine cooperatively. Later, she worked at Chinese Academy of Sciences Shanghai Institute of Materia Medica.
    Over 30 years of dedication in new drug development and research. Was awarded the first Prize for Science and Technology Progress by State Administration of Traditional Chinese Medicine in 1991 and National Awards for Science and Technology Grade I in 1992. Worked for Huiren Group as director of R&D Center for 5 years. Was awarded one of the top 10 employees by Huiren Group in 2006 and Excellent Management Individual of Provincial Technological Center during the “10th –five-year “by Jiangxi Province. Dr. Cai joined Medicilon in July 2008 and took on the position of BD Head of Chinese market and then Vice President of BD Department.

  • Xuedong Dai, Ph.D. EVP of International R&D

    Xuedong Dai, Ph.D. EVP of International R&D

    Dr. Xuedong Dai, Ph.D. in Organic Chemistry and Postdoctoral at MIT, has been deeply involved in the research and development of chemical drugs for central nervous system diseases, infectious diseases and tumor diseases for more than 20 years. Dr. Dai has a deep understanding and rich experience in the process of drug discovery, including the identification and optimization of seed compounds, and the development of high-quality clinical candidate compounds. Dr. Dai participated in the research and development of drugs including marketed drugs, such as Horizant®/Regnite®; clinical drugs, such as JNJ-75276617; and clinical candidate compounds, such as Arbaclofen Placarbil, XP21279, XP23829, etc.

  • Xingquan Ma, Ph.D. SVP of Chemistry

    Xingquan Ma, Ph.D. SVP of Chemistry

    Dr. Ma was awarded his Ph.D. degree in Bioorganic Chemistry from the prestigious Shanghai Institute of Organic Chemistry (SIOC), Chinese Academy of Science in 2001. Dr. Ma was further trained over 5 years in Medical Research in top academia organizations in the United stated, such as, as Associate Researcher in the Scripps Research Institute (TSRI) with Prof. M. G. Finn, and as Postdoctoral Research Fellow at the National Institutes of Health (NIH) with Dr. Pavol Kovac.
    Dr. Ma joined Shanghai ChemPartner, an internationally famous CRO company, as Senior Director in 2006, and joined Shanghai Medicilon as VP of Chemistry in 2008. During this period of 13 years’ CRO research, Dr. Ma significantly contributed to multitudinous drug discover projects, in which currently five compounds were in clinical research stage, and one approved to market by FDA. Dr. Ma has rich experience in carbohydrate chemistry and bio-chemistry, and their related areas. Dr. Ma has over 20 peer-reviewed publications.

  • Yongmei Xu Ph.D. R&D VP of Chemistry

    Yongmei Xu Ph.D. R&D VP of Chemistry

    Dr. Yongmei Xu, Ph.D. from Shanghai Organic Chemistry Institute of China Academy of Sciences, postdoctoral fellow at Stockholm University, Sweden, under the tutelage of Professor Bäckvall, Academician of the Royal Swedish Academy of Sciences. With more than 20 years of experience in drug discovery R&D, published 19 papers on internationally renowned academic journals such as Angew. Chem. Int. Ed., J. Org. Chem. and Chem. Commun.. Honored with the Tier 1 Shanghai Science and Technology Award in 2013. Since her service in Medicilon, Dr. Xu has been committed to drug discovery and led many projects of innovative pharmaceutical R&D such as anti-tumor medicine, the treatment of digestive tract diseases and diabetes, and has achieved remarkable results in the field of drug discovery.

  • Zhigang Li Ph.D. R&D VP of Chemistry

    Zhigang Li Ph.D. R&D VP of Chemistry

    Dr. Zhigang Li, Ph.D. in Applied Chemistry from Dalian University of Technology. Deeply engaged in research work in the State Key Laboratory of Applied Chemistry, published several papers in renowned academic journals such as Bioorg. Med. Chem., Tetrahedron. Won Shanghai Science and Technology Development Funds (B) in 2011. Applied about 20 patents in China, the United States, the European Union and the World Intellectual Property Organization. He is currently the Scientific research Vice President of Medicilon’s chemistry department. Responsible for medicinal chemistry, synthetic chemistry and other chemistry projects in drug discovery phase. Accumulated many experiences in synthesis of heterocycles, nucleosides and carbohydrates. Has worked with many domestic and foreign pharmaceutical companies and helped to advance these projects from lead optimization to pre-clinic candidate confirmation. Among them, the anti –tumor candidate PRT543 based on PRMT5 has entered phase I clinic trial in US; the second brain penetration BRAF inhibitor ABM-1310 also entered phase I clinic trial in US.

  • Zhenrong Guo Ph.D. Executive Vice President of Pharmacy

    Zhenrong Guo Ph.D. Executive Vice President of Pharmacy

    Dr. Zhenrong Guo, professor-level senior engineer; Ph.D. from University of Western Ontario, Canada; MBA, Fairleigh Dickinson University, USA; Post-Doctoral Fellow at Monell Chemical Senses Center and University of California, Berkeley, USA. Dr. Guo was the vice chairman of the Pharmaceutical Engineering Professional Committee of Zhejiang Pharmaceutical Association, and is currently an adjunct professor at Zhejiang University of Technology.

    Dr. Guo has been deeply involved in the field of innovative drug R&D for more than 30 years, and has rich experience in CMC R&D and management. Dr. Guo has successfully published 26 papers in top international journals, obtained a total of 33 patents in the United States orChina, undertook a number of major national new drug projects and major science and technology projects in Zhejiang Province, led the R&D and production of more than 10 new drugs, including the fields of tumor, diabetes and other major diseases. With his profound R&D technical strength and his industry contributions, Dr. Guo was awarded the “West Lake Friendship Award” in Zhejiang Province. Prior joining Medicilon, Dr. Zhenrong Guo served as a senior executive in well-known pharmaceutical companies such as Bristol-Myers Squibb (BMS), Zhejiang Jiuzhou Pharmaceutical, and Apeloa Pharmaceutical.

  • Xiaodong Zhang Ph.D. VP and Head of Preclinical Research

    Xiaodong Zhang Ph.D. VP and Head of Preclinical Research

    Dr. Xiaodong Zhang has nearly 20 years of experiences in non-clinical drug safety evaluation. Dr. Zhang received his PhD Degree in pharmacology from Institute of Basic Medical Science at Second Military Medical University. Before joining Medicilon, he was Deputy Director of the Department of Hygiene and Toxicology(Center of Evaluation for Drug Safety) at Second Military Medical University. As a Director leading the Study Director group to provide regulated GLP non-clinical safety evaluation packages for IND application. He is an expert in drug consulting group of Center for Drug Evaluation and the member of the Committee of Drug Toxicology & Safety Evaluation, CST, CPA and CNPHAS.

  • Baohong Cao Ph.D. VP of Pharmacology

    Baohong Cao Ph.D. VP of Pharmacology

    Over twenty-five years of combined professional experience in Academic research and Pharmaceutical industry and over 10 years of people/team manage experience. Surgery Ph.D. in Beijing Medical University, post-doctoral research associate at State Serum Institute, Copenhagen, Denmark. Dr. Cao used to do research work at University of Pittsburgh & Children’s Hospital of Pittsburgh, Benaroya Research Institute (Seattle) and Novartis Institutes of Biomedical Research. His work was published by top academic magazines, such as Nature Cell Biology, Nature Biotechnology and Journal of Cell Biology. Prior to Medicilon, Dr. Cao worked for Shanghai ChemPartner Co., Ltd. as senior director, MI Bioresearch Inc. as study operations director and Wuxi Apptech Inc. as senior director in Immune oncology.

  • Hong Wan Ph.D. Vice President of Pharmacokinetics and Bioanalysis Department

    Hong Wan Ph.D. VP of DMPK and Bioanalysis

    Dr. Hong Wan, PhD in analytical chemistry from Stockholm University, Sweden, has more than 20 years’ experience in Drug Discovery and CRO. He has extensive experiences in the fields of preclinical ADMET, DMPK, Toxicology and Bioanalysis for both small molecule drugs and large biologics, especially in oncology, immunotherapy, diabetes, CVGI, infectious diseases and central nervous system. He has authored and co-authored more than 50 publications in peer-reviewed journals. He was honored Associate Professor in the Department of Chemistry at Karlstad University in Sweden. He is Editorial Board members of ADMET/DMPK, Expert Opinion on Drug Metabolism & Toxicology. Dr. Wan is also the member of IAPC (International Association of Physical Chemists) Conference Organizing Committee and Co-chair of the 9th IAPC Conference.

    Prior to joining Medicilon, Dr. Wan served as the VP of DMPK and Toxicology of Sironax, the head of DMPK and Toxicology of Shanghai Hengrui Pharmaceutical Co. Ltd, and the senior management positions of Crown Biosciences Inc (Taicang) and AstraZeneca (Mölndal R&D, Sweden), respectively. Dr. Wan has considerable experience in preclinical evaluations, and has supported and accomplished dozens of PCC (Preclinical Candidate) and IND filing packages.

  • Xiancheng Zeng Ph.D. VP of Preclinical Toxicology Research

    Xiancheng Zeng Ph.D. VP of Preclinical Toxicology Research

    Dr. Xiancheng Zeng, senior engineer, MD from Shanghai Institute of Pharmaceutical Industry. In 2010-2013, he served in National Research Center of Drug Safety Evaluation, during which time he was sent to CFDA to get trained and practiced on NDA. In 2013, he joined Medicilon. He now is the vice president for Toxicity Research Dept., leading the research on the toxicity study of biotechnology drugs, vaccines and chemical drugs, as well as managing the whole research department. He has participated in and led the study of general toxicity and DMPK of the research and filing of 20 chemical drugs, 8 ADC, 10 monoclonal antibodies, 2 HCGs, 2 preventive vaccines and 1 compound medicine. In addition, he served as the project manager in 2 special studies of laboratory animals that were sponsored by Shanghai Committee of Science and one “Eleven-Five” prioritized special study.

  • Wenxin Dong Ph.D. VP of Pharmacology

    Dr. Wenxin Dong, Ph.D. in pharmacology of Université Paris VI and Académienationale de médecine de France. She was once a doctoral supervisor and fellow researcher in Shanghai Pharmaceutical Industry Research Institute, director of Shanghai Pharmaceutical Association, vice chairman of Shanghai Pharmacology Committee and one recipient of special allowances from the State Council. Dr. Dong has been engaged in pharmacological research and pharmaceutical innovation throughout her whole career, mainly in the fields of cardiovascular and cerebrovascular system and neuropsychiatric pharmacology. She presided over the establishment of a domestic leading technology platform for the pharmacology study of antidepressant and anti-Alzheimer's drugs, and established a technology platform for the pharmacology studies of analgesic, anti-anxiety and anti-Parkinson's disease drugs.

  • Christopher Stewart, DABT Ph.D. Senior Scientific Advisor

    Dr. Christopher Stewart, Postdoctoral Fellow in Toxicology, University of Arkansas School of Medicine; fellow of the American College of Toxicology and fellow of the Society of Toxicology, with over 30 years of professional experience. Dr. Stewart is currently the Principal Consultant of SGI Consulting. He has worked in research management for MPI Research, the world's largest preclinical CRO, Charles River Laboratories, Arkansas Children's Hospital, and the US FDA.

    He has extensive practice and deep insights into GLP regulations (including FDA, EPA, OECD and JMHLW) and ICH, and has made great achievements in the field of biomedical development. Dr. Stewart also participated in the preparation of more than 300 global application filing documents, and made positive contributions to the registration of chemical drugs and biological preparations, and the development of new drugs.